- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 125,78 | -0,19 % | Arcellx vor Übernahme durch Gilead: Letzter Quartalsbericht als eigenständiges Unternehmen erwartet | ||
| ZOETIS | 105,30 | -0,11 % | Zoetis to acquire animal genomics business from Neogen: The acquisition is expected to be completed in the second half of ... | ||
| INCYTE | 83,34 | -0,14 % | Incyte: European Commission Approves Zynyz For Anal Cancer Treatment | WASHINGTON (dpa-AFX) - Incyte (INCY) announced that the European Commission has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel, a platinum-based chemotherapy regimen... ► Artikel lesen | |
| CASSAVA SCIENCES | 1,845 | +1,23 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| AMARIN | 12,100 | -3,97 % | Here's Why I Wouldn't Touch Amarin With a 10-Foot Pole Given Its Patent and Competition Risks | ||
| ACHIEVE LIFE SCIENCES | 3,700 | +1,65 % | Achieve Life Sciences: Entscheidet der 20. Juni über Leben und Tod? | Seit unseres Trading-Tipps im Juli letzten Jahres konnte die Aktie von Achieve Life Sciences zwischenzeitlich über +150% zulegen, korrigierte in den letzten Wochen aber wieder um mehr als 20%. Das Unternehmen... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 178,00 | -0,56 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 372,70 | -0,19 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ANI PHARMACEUTICALS | 63,50 | -1,55 % | 833K Reasons To Be Bullish On ANI Pharmaceuticals Stock | ||
| ENZON PHARMACEUTICALS | 0,001 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock | ||
| TALPHERA | 0,747 | -1,45 % | Talphera, Inc.: Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial | Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites
Company to host a virtual investor and analyst... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 24,200 | 0,00 % | Rigel Pharmaceuticals, Inc.: Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025... ► Artikel lesen | |
| SAVARA | 4,700 | +0,43 % | Savara receives FDA day 74 letter for autoimmune PAP drug | ||
| BIODEXA PHARMACEUTICALS | 0,906 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients | ||
| ARTIVION | 31,900 | +2,57 % | Marshall Stanton Implements A Sell Strategy: Offloads $81K In Artivion Stock |
CORNERSTONE THERAPEUTICS INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.